BioSpace News Archive

SteriPack Group, a leading global contract manufacturer serving the medical device, pharmaceutical, and diagnostic markets, announces they have won an Edison Award in the category Covid-19 Innovation.

They can be found in cosmetics, plastic containers, furniture, toys, or baby bottles.

BIOLASE, Inc., announced that it held its annual meeting of stockholders on April 28, 2022 where the Company’s stockholders granted the Board of Directors the discretion to effect a reverse stock split of the Company’s common stock at a ratio between 1-to-2 and 1-to-25.

Forming an academic-industry collaboration, the project will combine virology expertise of Dr. Anil Kumar, University of Saskatchewan with API’s expertise in drug development to identify new lead compounds that could pave the way for novel antivirals against SARS-CoV-2 variants.

Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report first quarter 2022 financial results and corporate highlights after the close of market on Thursday, May 5, 2022.

ERYTECH Pharma announced that it had filed its 2021 Universal Registration Document for the year ended December 31, 2021, including the management report and the annual financial report with the “Autorité des Marchés Financiers” and its Annual Report on Form 20-F for the year ended December 31, 2021 with the U.S.

Inari Medical, Inc. announced that its management team will present at the Bank of America 2022 Healthcare Conference on Thursday, May 12, 2022 at 10:40 a.m. Pacific Time at the Encore Hotel in Las Vegas.

Seer, Inc., a life sciences company commercializing a disruptive new platform for proteomics, announced that the company will be participating in the upcoming BofA Securities 2022 Healthcare Conference in Las Vegas, Nevada.

Prothena Corporation plc announced that it will report its first quarter 2022 financial results on Thursday, May 5, 2022 after the close of the U.S. financial markets.

Nkarta, Inc. announced the closing of its previously announced underwritten public offering of 13,333,334 shares of its common stock at a price to the public of $15.00 per share, and the exercise in full by the underwriters of their option to purchase an additional 2,000,000 shares of common stock.